Susmitha Apuri

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Lisa Zimmer, Susmitha Apuri, Zeynep Eroglu et al. · European Journal of Cancer · 2017 · 179 citations

Anti-pd-1 Therapy, Medicine, Melanoma +8

Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review

Susmitha Apuri, Kristin Carlin, Edward Bass et al. · Mediterranean Journal of Hematology and Infectious Diseases · 2014 · 33 citations · Full text

Neurological Disorder, Bone Marrow Transplant, Immunology +23

Expression of the BAD pathway is a marker of triple-negative status and poor outcome

Bernadette M. Boac, Forough Abbasi, Roohi Ismail‐Khan et al. · Scientific Reports · 2019 · 26 citations · Full text

Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome

Susmitha Apuri, Najla Al Ali, Eric Padron et al. · Clinical Lymphoma Myeloma & Leukemia · 2017 · 17 citations

Hematological Malignancy, Hypomethylating Agents, Bone Marrow Failure +7

Evidence for selective benefit of sequential treatment with azanucleosides in patients with myelodysplastic syndromes (MDS).

Rami S. Komrokji, Susmitha Apuri, Najla Al Ali et al. · Journal of Clinical Oncology · 2013 · 11 citations

Cancer Management, Pharmacotherapy, Selective Benefit +18